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Chordoma is a rare tumor originating from notochordal remnants that is usually diagnosed during midlife. We
performed a genomewide analysis for linkage in a family with 10 individuals affected by chordoma. The maximum
two-point LOD score based on only the affected individuals was 2.21, at recombination fraction 0, at marker
D7S2195 on chromosome 7q. Combined analysis of additional members of this family (11 affected individuals)
and of two unrelated families (one with 2 affected individuals and the other with 3 affected individuals), with 20
markers on 7q, showed a maximum two-point LOD score of 4.05 at marker D7S500. Multipoint analysis based
on only the affected individuals gave a maximum LOD score of 4.78, with an approximate 2-LOD support interval
from marker D7S512 to marker D7S684. Haplotype analysis of the three families showed a minimal disease-gene
region from D7S512 to D7S684, a distance of 11.1 cM and ∼7.1 Mb. No loss of heterozygosity was found at
markers D7S1804, D7S1824, and D7S2195 in four tumor samples from affected family members. These results
map a locus for familial chordoma to 7q33. Further analysis of this region, to identify this gene, is ongoing.
Chordomas (MIM 215400) are rare, slow growing, and
locally invasive bone tumors thought to be derived from
notochordal remnants (Malawer et al. 1997). There is
a modest overall male predominance (1.7:1), which is
more striking (∼3:1) among patients with sacral chor-
domas. The age distribution at diagnosis is unimodal,
with a median of 59 years. Treatment of chordomas is
predominantly surgical, followed by radiotherapy (Rich
et al. 1985; Healey and Lane 1989; Tai et al. 1995).
Survival rates to 5 and 10 years are 68% and 40%,
respectively (McMaster et al. 2001).
Little is known about either the molecular biology of
chordoma or the etiologic factors that predispose to it.
No characteristic karyotypic abnormality has been de-
scribed in primary chordomas (Sawyer et al. 2001). That
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an alteration in one or more genes may play a role is
suggested by reports of five families with chordoma in
two or more close relatives. The affected relatives in-
cluded a middle-aged brother and sister with sacral chor-
doma (Foote et al. 1958), two young brothers with na-
sopharyngeal chordoma (Enin 1963), a man with
nasopharyngeal chordoma whose mother and daughter
developed the same tumor (Kerr et al. 1975), a man with
sacral chordoma whose sister and niece developed clival
chordomas and whose first cousin had a nasopharyngeal
chordoma (Stepanek et al. 1998), and a father and
daughter with clival chordoma (Dalpra et al. 1999;
Miozzo et al. 2000). We have performed genomewide
linkage analysis using the extended pedigree of the fam-
ily reported by Stepanek et al. (1998) and have identi-
fied, on chromosome 7q33, a putative locus for familial
chordoma.
We clinically evaluated the 4 living index cases with
histopathologically confirmed chordoma (individuals III-
3, III-5, III-14, and IV-1 in family 1; see fig. 1) and 14
blood relatives from the family reported by Stepanek et.
al. (1998), under an institutional review board–approved
protocol. Magnetic resonance (MR) images of the pitui-
tary/sella tursica, spine, sacrum, and coccyx demonstrated
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Figure 1 Pedigree of family 1. The four index cases are indicated by arrows. All affected individuals had clival chordoma, except for
individual III-3, who had a sacral chordoma. Deceased individuals (indicated by a diagonal line through the symbol) and individual III-6 were
not genotyped. An asterisk (*) denotes that a DNA sample was obtained.
Figure 2 Pedigrees of families 2 (A) and 3 (B). Symbols are as
described in the legend to table 1.
a clival or nasopharyngeal mass, suggestive of chordoma,
in 6 of the 14 screened relatives. This diagnosis was con-
firmed histopathologically in three relatives who under-
went tumor excision (D. M. Parry, unpublished data). Of
the 10 confirmed or suspected cases of chordoma in this
family, 9 involve the clivus or nasopharynx. The pattern
of inheritance, including father-to-son transmission, is
compatible with an autosomal dominant trait.
We isolated genomic DNA from peripheral lympho-
cytes and performed genomewide genotyping in 22 in-
dividuals (II-1–II-6, III-1–III-3, III-5, III-7–III-16, IV-1,
and IV-2) of family 1, using the 365 autosomal- and 2
sex-chromosome simple tandem repeat (STR) markers
of The Cooperative Human Linkage Center’s version 8
marker set (average spacing 10 cM; average heterozy-
gosity .76), according to a standard PCR protocol (Re-
search Genetics), and a Perkin-Elmer ABI 310 genetic
analyzer and GENESCAN and GENOTYPER software.
We performed two-point LOD-score linkage analysis,
using the MLINK and ILINK programs from the LINK-
AGE package, version 5.10 (Lathrop et al. 1984), under
the assumption of autosomal dominant inheritance of a
rare allele with population frequency .0001. Because es-
timates of penetrance for familial chordoma are un-
known, we performed the analysis under four different
scenarios. In the first analysis, we used phenotype data
on only the 10 affected individuals (7 with biopsy–
proved chordoma and 3 with MR-imaging findings sus-
picious for chordoma), in an affecteds-only analysis in
which we coded all clinically unaffected individuals as
“unknown” with respect to disease status. The remain-
ing three analyses included all 22 family members (af-
fected, unaffected, and spouses), and we assumed
non–age-dependent penetrances of 100%, 75%, and
50%. In these preliminary analyses, marker loci were
assumed to be codominant, with n equally frequent al-
leles, where n p (no. of observed alleles)  1. The ad-
ditional allele at the marker locus was included to ac-
count for the fact that individuals I-1 and I-2 were not
Figure 3 Multipoint LOD-score plot of the region, in chromosome 7, of the gene for familial chordoma, in family 1 alone (A) and in
the three families combined (B), under an affecteds-only analysis using GENEHUNTER (Kruglyak et al. 1996).
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Table 1
Chromosome 7 Linkage Analysis: Two-Point Parametric LOD Scores and Corresponding v’s for
Three Families with Chordoma
MARKER
LOD SCORE (v) FOR
Penetrance
GENETIC-MAP
POSITIONa
(cM) Affecteds Only 100% 75% 50%
D7S1842 170.3 .59 (.2) .20 (.4) .29 (.3) .41 (.3)
D7S2203 172.7 .38 (.2) .23 (.3) .39 (.2) .42 (.2)
D7S530 178.2 1.29 (.1) .89 (.2) 1.03 (.2) 1.17 (.1)
D7S512 179.7 .92 (.1) .29 (.2) .68 (.1) .83 (.1)
D7S1804b 180.6 3.62 (0) .98 (.2) 2.02 (.01) 3.08 (0)
D7S631 182 1.47 (0) 1.24 (.1) 1.13 (.05) 1.19 (.05)
D7S500 184.2 4.05 (0) 1.29 (.2) 2.19 (.05) 3.17 (0)
D7S509 186.9 4.01 (0) 2.73 (.1) 3.11 (.05) 3.67 (0)
D7S495 188.3 1.54 (0) .57 (.2) .80 (.1) 1.05 (.05)
D7S684 190.8 1.69 (.05) .27 (.3) .67 (.2) 1.20 (.1)
D7S2505 191.7 3.53 (0) 1.18 (.2) 1.70 (.1) 2.57 (0)
D7S2202 193.5 3.20 (0) .77 (.2) 1.48 (.1) 2.31 (0)
D7S1824 193.5 2.20 (.05) .49 (.3) 1.16 (.1) 1.75 (.05)
D7S2513 194.8 3.14 (.05) 1.03 (.2) 1.84 (.1) 2.45 (.05)
D7S2195 200.1 2.85 (.05) 1.39 (.2) 2.04 (.1) 2.46 (.05)
D7S661 202.1 1.62 (.05) .15 (.3) .54 (.2) 1.05 (.1)
D7S1798 202.7 .47 (.2) .05 (.3) .21 (.2) .35 (.2)
D7S2511 203.3 2.51 (.05) 1.59 (.2) 1.94 (.1) 2.16 (.1)
D7S688b,c 206.5 .54 (.2) .35 (.2) .43 (.2) .49 (.2)
D7S2426 207 1.28 (.1) .27 (.3) .36 (.3) .60 (.2)
D7S505 217.5 .38 (.2) .09 (.4) .16 (.3) .24 (.3)
a Based on the Center for Medical Genetics (Marshfield Medical Research Foundation) gender-
averaged genetic map. Marker order was confirmed by reference to a physical map (Bouffard et al.
1997).
b Allele frequencies were not available from either CEPH (Fondation Jean Dausset) or the Center
for Human Genetics (Duke University Medical Center) and, therefore, are assumed to be equal.
c Family 1 only.
available to be genotyped. We also performed the non-
parametric affected-sib-pair (ASP) test and the Hase-
man-Elston (HE) sib-pair test (Haseman and Elston
1972), using the S.A.G.E program SIBPAL (SAGE1994).
Results of the genomewide screen in 22 individuals
from family 1 suggested possible linkage of the disease
gene to chromosomes 4, 7, 17, or 19, on the basis of
either two-point LOD scores 1.0 or , for sib-P  .01
pair analyses at each of two adjacent marker loci. The
greatest two-point LOD scores for each of the four chro-
mosomes were 1.85 at marker D4S1627 (recombination
fraction [v] 0 under the assumption of 50% penetrance),
2.21 at marker D7S2195 ( under affecteds-onlyvp 0
analysis), 1.51 at marker ATC6A06 ( under thevp .09
assumption of 100% penetrance), and 1.03 at marker
D19S714 ( when all affection-status scenarios con-vp 0
sidered), respectively. Additional STR markers at ∼2-cM
intervals were genotyped in each of these four regions.
The greatest evidence for linkage was found on chro-
mosome 7 in the affecteds-only analysis, where the max-
imum two-point LOD score was 2.26 at at markervp 0
D7S500. The nonparametric P values were ∼.01 for the
ASP test and were not significant for the HE test. Mul-
tipoint analysis using LINKMAP (Lathrop et al. 1984)
gave the greatest evidence for linkage in the affecteds-
only analysis, a maximum LOD score of 2.34 at marker
D7S2195. All affected family members shared a com-
mon haplotype at 12 markers in a 23.6-cM region on
chromosome 7q32-34. In contrast, linkage analysis of
additional markers in the studied regions on chromo-
somes 4, 17, and 19 did not result in higher two-point
LOD scores and did not reveal a common haplotype
shared by all 10 affected individuals. Specifically, no ad-
ditional markers on chromosomes 17 or 19 and only
one new marker on chromosome 4 (marker D4S1553;
LOD score 1.49 at in affecteds-only analysis)vp 0
yielded a LOD score 11 in the 2-cM screen. These three
regions no longer showed consistent evidence for
linkage.
To increase the power of the linkage analysis and to
narrow the suspected disease-gene region, we examined
additional members of family 1 (individuals IV-3–IV-5;
see fig. 1) and ascertained two smaller, independent fam-
ilies with chordoma, families 2 and 3 (fig. 2). Individual
IV-3 in family 1 had a clival mass that was excised and
confirmed as chordoma. In family 2, the two index cases
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Table 2
Disease Haplotypes of Affected Individuals and Obligate Carriers, by Nuclear Family
MARKERa
ALLELE INb
Family 1 Family 2 Family 3
II-1 III-1 III-3 III-5 IV-1 IV-2 IV-3 II-3 II-6 III-14 III-16 III-1 IV-1 II-4 IV-3 II-2 III-2 II-3 III-3 III-4
D7S1842 7 7 7 7 7 7 7 2 2 6 2 6 6 6 3 3 3 3 3 3
D7S2203 2 2 2 2 2 2 2 1 1 1 1 3 3 3 3 3 3 3 3 3
D7S530 4 4 4 4 4 4 4 2 2 3 2 3 3 3 3 6 6 6 6 6
D7S512 2 2 2 2 2 2 2 2 6 7 6 2 2 2 2 8 8 8 8 8
D7S1804 2 2 2 2 2 2 2 2 2 2 2 4 4 4 4 4 4 4 4 4
D7S631 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2
D7S500 6 6 6 6 6 6 6 6 6 6 6 1 1 1 1 9 9 9 9 9
D7S509 3 3 3 3 3 3 3 3 3 3 3 5 5 5 5 4 4 4 4 4
D7S495 1 1 1 1 1 1 1 1 1 1 1 5 5 5 5 2 2 2 2 2
D7S684 2 2 2 2 2 2 2 2 2 2 2 4 4 4 4 5 5 3 3 3
D7S2505 5 5 5 5 5 5 5 5 5 5 5 4 4 4 4 4 4 4 4 4
D7S2202 2 2 2 2 2 2 2 2 2 2 2 6 6 6 6 6 6 5 5 5
D7S1824 4 4 4 4 4 4 4 4 4 4 4 1 1 1 1 6 6 3 3 3
D7S2513 3 3 3 3 3 3 3 3 3 3 3 9 9 9 9 1 1 2 2 2
D7S2195 4 4 4 4 4 4 4 4 4 4 4 1 1 1 1 2 2 3 3 3
D7S661 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 6 6 6
D7S1798 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 1 1 2 2 2
D7S2511 4 4 4 4 4 4 4 4 4 4 4 4 4 6 6 3 3 3 3 3
D7S688 5 5 5 5 5 5 5 4 4 4 4 … … … … … … … … …
D7S2426 5 5 5 5 5 5 5 4 4 4 4 3 3 3 3 3 3 3 3 3
D7S505 2 2 2 1 2 2 2 2 2 2 2 1 … 2 2 4 4 1 1 1
a Marker order was confirmed by reference to a physical map of chromosome 7 (Bouffard et al. 1997).
b The haplotype regions shared within each family are boxed. An ellipsis (…) indicates that the marker was not studied.
(individual III-1 and his paternal first cousin once re-
moved, individual IV-3) had histologically confirmed cli-
val chordoma. In addition, individual IV-1, the daughter
of individual III-1, had a pilocytic astrocytoma. Of the
living relatives in family 3, the index cases (individual
III-3 and her first cousin, individual III-2) had histo-
pathologically confirmed clival chordoma, and, on MR
imaging, individual III-4 (the brother of individual III-
3) had a clival mass consistent with chordoma. Family
3 is a branch of a three-generation family with chordoma
that has been reported elsewhere (Kerr et al. 1975; E.S.,
unpublished data). In subsequent linkage analyses, we
extended the definition of “affected” to include the pa-
tient in family 2 who had astrocytoma. This decision
was based on the similar occurrence of juvenile astro-
cytoma in a child whose sister and father had clival
chordoma (Dalpra et al. 1999; Miozzo et al. 2000).
We genotyped a total of 41 individuals from the three
families, for 21 chromosome 7 markers over a span of
∼47 cM; for 19 of these markers, we used available
allele-frequency estimates from CEPH (Fondation Jean
Dausset) and the Center for Human Genetics (Duke Uni-
versityMedical Center), and for the remaining 2markers
we used alleles that we assumed to be equifrequent. For
family 1 alone, the highest two-point LOD score was
2.58 at at marker D7S2195, in the affecteds-vp 0
only analysis. Multipoint linkage analysis using GENE-
HUNTER (Kruglyak et al. 1996) and considering only
the affected individuals in family 1 revealed an approx-
imate 2-LOD support interval from D7S512 to D7S688
(fig. 3A). When the three families were analyzed together,
under the assumption of locus homogeneity, two-point
LOD scores 13 were found at markers D7S1804,
D7S500, D7S509, D7S2505, D7S2202, and D7S2513,
in the affecteds-only analysis (table 1). Multipoint link-
age analyses of markers D7S1842 to D7S505 revealed
a maximum LOD score of 4.78 when GENEHUNTER
was used. An ∼2-LOD support interval extended from
D7S512 to D7S684, with the peak being obtained when
the disease gene was coincident with D7S509 (fig. 3B).
Similar results were obtained when the programs LINK-
MAP and VITESSE (O’Connell and Weeks 1995) were
used (data not shown).
In the additional members of family 1, there were no
recombination events in the disease-gene region. Thus,
the minimal disease-gene region for this family remained
the interval from D7S512 to D7S688 (table 2). Haplo-
type analysis of family 2 showed that the three affected
individuals and the obligate carrier (individual II-4)
share a common haplotype from marker D7S2203 to
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Table 3
LOH Analysis in Four Samples of Chordoma
Tumor from Family 1
MARKER
LOH STATUS INa
II-1b II-6b III-3c III-16b
Chromosome 4:
D4S2639 
GATA10G07  NI  NI
D4S2361    
D4S1647 NI NI  
D4S1625 
Chromosome 7:
D7S1804    
D7S1824    
D7S2195    
Chromosome 17:
D17S1851    
ATC6A06    
D17S1820    
Chromosome 19:
D19S558    
D19S1165    
D19S930    
a  p Presence of LOH;  p absence of LOH;
NI p not informative.
b Sample was from the primary tumor.
c Sample was from a skin metastasis of the sacral
primary tumor.
D7S661 (table 2), so that the minimal disease-gene re-
gion in this family extends from marker D7S1842 to
marker D7S1798, a genetic distance of 32.4 cM on the
gender-averaged Center for Medical Genetics (Marsh-
fieldMedical Research Foundation) genetic map. In fam-
ily 3, the three affected individuals and two obligate
carriers (individuals II-2 and II-3) share a common hap-
lotype from marker D7S1842 to marker D7S495 (table
2). Thus, the corresponding minimal disease-gene region
extends from centromeric of marker D7S1842 tomarker
D7S684. Under the assumption of locus homogeneity in
the three families, haplotype analysis identified the min-
imal disease-gene region as extending from marker
D7S512 to D7S684, a genetic distance of ∼11 cM. We
confirmed the marker order by reference to a physical
map of the region, consisting of YAC clones (Bouffard
et al. 1997). The physical size of the minimal disease-
gene region is ∼7.1Mb. There are 14 known or predicted
genes in this region (not including potential genes with
a single expressed-sequence tag).
As an alternative way to confirm and potentially nar-
row the region containing the putative chordoma gene,
we looked for allelic loss of the non–disease-associated
haplotype within microdissected tumor cells from flash-
frozen chordoma tissue from individuals II-1, II-6, III-
3, and III-16 in family 1. Between three and five infor-
mative microsatellite markers on chromosomes 4, 7, 17,
and 19, from each of the regions initially suggested to
be linked to the disease gene were analyzed for loss of
heterozygosity (LOH); under the conditions utilized, we
could detect LOH if (a) blood and paired-tumor-cell
DNA amplification was successful and produced con-
sistent results in at least two attempts and (b) there was
140% loss of one allele versus the other allele. No LOH
was found at any of three markers on chromosomes 7,
17, and 19; however, tumor cells from a skin metastasis
in individual III-3 had LOH at markers on chromosome
4 (table 3). Without LOH for the markers on chromo-
some 7, we could not narrow the region suspected to
carry the chordoma gene. However, this absence of LOH
may indicate that the disease gene exerts its oncogenic
effect in a dominant fashion. Alternatively, the markers
may be too far from the disease gene, or LOHmay occur
over a very small region.
Because of its role as a secreted growth-and-differ-
entiation factor, we selected the pleiotrophin gene, PTN,
as the first gene to sequence. When we began, only par-
tial genomic-structure information was available for this
gene (GenBank accession numbers S50394, S50404,
S50405, S50408, and S50409). We determined addi-
tional intronic sequence by amplifying across the in-
trons, using oligonucleotides in the coding regions and
performing direct sequencing on the PCR products. Oli-
gonucleotide primers amplifying the four coding exons
of the human pleiotrophin gene were designed by use of
these intronic sequences. We used DNA-sequence anal-
ysis to examine the coding region (exons 2–5) and the
adjacent splice sites of PTN, for sequence variants in
genomic DNA from two affected members of family 1
and from one unrelated individual. No variants were
found, suggesting that PTN is not a gene for familial
chordoma.
We are continuing to sequence other candidate genes
in the region, in DNA from affected members of all three
families. In addition, we are seeking additional families
with chordoma, for linkage studies to further fine-map
this chordoma locus.
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